Real-world effectiveness and safety of avelumab first-line maintenance (1LM) treatment in patients with locally advanced or metastatic urothelial carcinoma (la/mUC): Second interim analysis of the AVENUE study.

被引：0

作者：

Goebell, Peter J.

Sultanbaev, Alexander Valerievich

Brachtel, Anna Leena

Molina, Aurea

Lorente, David

Zihler, Deborah

Wang, Lusha

Kostkova, Lenka

Hoffman, Jason

Cremer, Laura

Gschwend, Juergen E.

机构：

[1] Univ Hosp Erlangen, Dept Urol & Pediat Urol, Erlangen, Germany

[2] Republican Clin Oncol Dispensary, Dept Chemotherapy, Ufa, Russia

[3] St Vincent Hosp, Dept Urol, D-30559 Hannover, Germany

[4] Univ Hosp A Coruna, Dept Med Oncol, La Coruna, Spain

[5] Inst Valenciano Oncol, Dept Med Oncol, Valencia, Spain

[6] Cantonal Hosp Aarau, Dept Med Oncol Hematol & Transfus Med, CH-5001 Aarau, Switzerland

[7] Merck Serono Co Ltd, Beijing, Peoples R China

[8] Merck KGaA, Darmstadt, Germany

[9] Healthcare Business Merck KGaA, Darmstadt, Germany

[10] EMD Serono Inc, Billerica, MA USA

[11] Merck Healthcare Germany GmbH, Weiterstadt, Germany

[12] Tech Univ Munich, Sch Med, Dept Urol, Klinikum Rechts Isar, Munich, Germany

来源：

关键词：

D O I：

10.1200/JCO.2025.43.5_suppl.706

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：1